Quarterly report pursuant to Section 13 or 15(d)

Acquisitions (Tables)

v3.10.0.1
Acquisitions (Tables)
9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Schedule of Assets Acquired and Liabilites Assumed

The following table shows the preliminary allocation of the purchase price of Jamestown Regional Medical Center to the acquired identifiable assets acquired, and liabilities assumed:

 

 

Total purchase price   $ 668,983  
Tangible and intangible assets acquired, and liabilities assumed at estimated fair value:        
Cash   $ -  
Inventories     450,682  
Prepaids and deposits     310,385  
Property and equipment     7,347,468  
Intangible assets     486,716  
Accrued expenses     (193,966 )
Net tangible and intangible assets acquired   $ 8,401,285  
Gain on bargain purchase   $ 7,732,302  

Schedule of Unaudited Pro-forma of Results of Operations

The following presents the unaudited pro-forma combined results of operations of the Company and Jamestown Regional Medical Center as if the acquisition had occurred on January 1, 2017.

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2017     2018     2017  
    (unaudited)     (unaudited)  
Net revenue   $ 4,606,295     $ 15,367,565     $ 13,042,346  
Net income (loss) from continuing operations     (10,581,164 )     (6,098,958 )     (30,956,920 )
Net income (loss)     (11,589,123 )     (5,983,171 )     (33,709,088 )
Deemed dividend from trigger of down round provision feature     (2,280,280 )     (17,942,578 )     (53,341,619 )
Net income (loss) to common shareholders   $ (13,869,403 )   $ (23,925,749 )   $ (87,050,707 )
                         
Net income (loss) per common share:                        
Basic continuing operations   $ (4,400.39 )   $ (2.39 )   $ (22,648.83 )
Diluted continuing operations   $ (4,400.39 )   $ (2.39 )   $ (22,648.83 )
Basic net income (loss)   $ (5,767.87 )   $ (9.38 )   $ (63,688.40 )
Diluted net loss   $ (5,767.87 )   $ (9.38 )   $ (63,688.40 )
Weighted average number of common shares outstanding during the period:                        
Basic     2,405       2,550,632       1,367  
Diluted     2,405       2,550,632       1,367